Free Trial

Royal Bank Of Canada's Rating of Ionis Pharmaceuticals on 7/13/2026

On July 13, 2026, Royal Bank Of Canada updated its outlook on Ionis Pharmaceuticals (NASDAQ:IONS) with the action "Lower Price Target", setting a price target of $85.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Royal Bank Of Canada

DateCompanyAction
10/16/2026
Kodiak Gas Services, Inc. stock logo
KGS
Kodiak Gas Services
Lower Price Target
10/16/2026
TransUnion stock logo
TRU
TransUnion
Lower Price Target
10/16/2026
Fair Isaac Corporation stock logo
FICO
Fair Isaac
Lower Price Target
10/16/2026
Equifax, Inc. stock logo
EFX
Equifax
Lower Price Target
10/16/2026
West Fraser Timber Co. Ltd. stock logo
WFG
West Fraser Timber
Lower Price Target
10/16/2026
Sylvamo Corporation stock logo
SLVM
Sylvamo
Lower Price Target
More Ratings From Royal Bank Of Canada